

# Why is depression more prevalent in women?

Paul R. Albert, PhD

Major depression is a chronic illness with a high prevalence and is a major component of disease burden. Depressive disorders were the second leading cause of years lived with disability in 2010 in Canada, the United States and globally.<sup>1,2</sup> When depression-related deaths due to suicide and stroke are considered, depression has the third highest global burden of disease.<sup>3</sup> Major depression is growing in overall disease burden in Canada and around the world; it is predicted to be the leading cause of disease burden by 2030, and it is already the leading cause in women worldwide.<sup>4</sup> Between 1990 and 2010 in Canada, major depressive disorder showed a 75% increase in disability-adjusted life years,<sup>1</sup> the second greatest increase in prevalence after Alzheimer disease; in comparison, the increase in the United States was 43%.<sup>2</sup> At the same time, the female:male ratio of global disability from major depression remained unchanged at 1.7:1. Although differences in socioeconomic factors, including abuse, education and income, may impact the higher rate of depression in women,<sup>5</sup> this editorial focuses on biological contributors that are experimentally tractable and may help to understand how and why depression is more prevalent in women and lead to better treatments.

The prevalence of major depression is higher in women than in men;<sup>6,7</sup> in 2010 its global annual prevalence was 5.5% and 3.2%, respectively, representing a 1.7-fold greater incidence in women.<sup>1,8</sup> In Canada, the prevalence was 5.0% in women and 2.9% in men in 2002 (1.7-fold greater incidence in women) and increased to 5.8% and 3.6%, respectively, in 2012 (1.6-fold greater incidence in women).<sup>9,10</sup> The finding of similar female:male prevalence ratios in developed countries and globally suggests that the differential risk may primarily stem from biological sex differences and depend less on race, culture, diet, education and numerous other potentially confounding social and economic factors. There is no clear evidence that the rate of depression is greater in countries where women have markedly lower socioeconomic status than men than in countries where there may be more equal footing.<sup>5</sup> Depression is more than twice as prevalent in young women than men (ages 14–25 yr), but this ratio decreases with age.<sup>9,10</sup> Indeed, starting at puberty, young women are at the greatest risk for major depression and mental disor-

ders globally.<sup>1</sup> Importantly, before puberty, girls and boys have similar rates of depression; the rate is perhaps even higher for boys.<sup>6</sup> At ages older than 65 years, both men and women show a decline in depression rates, and the prevalence becomes similar between them.<sup>9,11</sup> A greater prevalence of depression in women is also reflected in prescriptions for antidepressant medications. In Canada between 2007 and 2011, antidepressants were prescribed more than twice as often to women than men (9.3% v. 4.2% in patients aged 25–44 yr, 2.2-fold; 17.2% v. 8.2% in patients aged 45–64 yr, 2.1-fold).<sup>12</sup> The age discrepancy between the peaks in the prevalence of depression (age 14–25 yr)<sup>10</sup> and the prevalence of antidepressant use (> 45 yr) suggests that young adults with depression may not always receive antidepressant treatment until many years after the onset of illness. This delay in medication could contribute to the higher rates of depression during adolescence and young adulthood and would be important to study more rigorously comparing treated and nontreated cohorts. Delay in antidepressant treatment might reflect stigma or underdiagnosis in adolescence. New antistigma and educational programs targeted to youth may help reduce depression in this age group.<sup>13</sup>

Why then is depression more prevalent among women? The triggers for depression appear to differ, with women more often presenting with internalizing symptoms and men presenting with externalizing symptoms.<sup>14</sup> For example, in a study of dizygotic twins, women displayed more sensitivity to interpersonal relationships, whereas men displayed more sensitivity to external career and goal-oriented factors.<sup>15</sup> Women also experience specific forms of depression-related illness, including premenstrual dysphoric disorder, postpartum depression and postmenopausal depression and anxiety, that are associated with changes in ovarian hormones and could contribute to the increased prevalence in women. However, the underlying mechanisms remain unclear; thus, treatments specific to women have not been developed.

The fact that increased prevalence of depression correlates with hormonal changes in women, particularly during puberty, prior to menstruation, following pregnancy and at perimenopause, suggests that female hormonal fluctuations may be a trigger for depression. However, most preclinical

**Correspondence to:** P. Albert, Department of Neuroscience, Ottawa Hospital Research Institute, University of Ottawa, 451 Smyth Rd, Ottawa ON K1H 8M5; palbert@uottawa.ca

DOI: 10.1503/jpn.150205

©2015 8872147 Canada Inc.

studies focus on males to avoid variability in behaviour that may be associated with the menstrual cycle. Nevertheless, primate and rodent studies consistently implicate a role for female hormones, such as estrogen, in depression. Perhaps the most naturalistic depression studies to date to address the role of female hormones involved small groups ( $n = 4-5$ ) of female macaque primates that formed lifelong social hierarchies with dominant and subordinate females. The latter showed a depression-like phenotype<sup>16</sup> that has been associated with a brain-wide decrease in serotonin 1A (5-HT<sub>1A</sub>) receptor levels and decreased hippocampal volume.<sup>17,18</sup> Interestingly, the reduced hippocampal volume was more extensive in postmenopausal monkeys than in ovarian-intact monkeys, suggesting that ovarian function may be protective. Consistent with this finding, the risk of depression appears to increase during the perimenopausal transition.<sup>19</sup> Emerging evidence indicates that hormone replacement therapy, particularly during the perimenopausal period, can be effective in the prevention of postmenopausal depression in women.<sup>20</sup> Another study involving female macaques examined relocation stress-sensitive alterations in their menstrual cycles and showed depression-related behaviours and reductions in the function of the brain serotonin system.<sup>21</sup> In this light, a recent study has indicated that women who reported using an oral contraceptive (especially monophasic contraceptives) showed reduced rates of major depression and anxiety compared with nonusers,<sup>22</sup> suggesting that moderating the cycling of estrogen may be protective. Taken together these studies suggest that estrogen may have a protective effect on the pathology that underlies depression and that decreases in estrogen may increase the risk for depression.

Why then do men, who lack systemic estrogen, have lower rates of depression than women? Accumulating research has shown that in the male brain testosterone is converted into estrogen by endogenous aromatase (CYP19). Estrogen could mediate protective actions through estrogen receptors expressed throughout the male brain (especially estrogen receptor  $\beta$ ).<sup>23</sup> In addition, the presence of androgen receptors in men may confer protection, for example in hippocampal neurons.<sup>24</sup> Since testosterone does not cycle in men as estrogen does in women, there may be a more consistent protection in men. However, men also have sexually dimorphic brain nuclei, particularly in the hypothalamus, so the lower prevalence of depression in men is probably more complex owing not only to hormonal differences, but also to developmental differences in brain circuitry.<sup>23</sup>

In the most fundamental terms, the sex difference in depression rates reflects the fact the men and women are different: women have 2 copies of the X chromosome, while men have 1 copy each of X and Y chromosomes, the latter not being present in women. Understanding how this fundamental genetic difference confers sexual differences in predisposition to mental illness is a complex, multilevel puzzle that remains to be clarified. Society-driven risk factors for depression in women likely have a biological origin, such as differences in physical strength and personality traits, leading to a higher prevalence of

depression in women. Perhaps what needs to change are social attitudes to promote equality; yet, this has been occurring in the West and has yielded no clear change in the female:male depression ratio.<sup>5</sup> However, despite this complexity, recent evidence suggests that biological factors, such as the variation in ovarian hormone levels and particularly decreases in estrogen, may contribute to the increased prevalence of depression and anxiety in women and that strategies to mitigate decreases in estrogen levels may be protective. Identifying ligands that more specifically target the brain (e.g., estrogen receptor- $\beta$ -selective ligands) may protect from depression but avoid adverse effects of estrogen therapy.<sup>25</sup>

**Affiliations:** From the Department of Neuroscience, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.

**Competing interests:** None declared.

## References

1. Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. *Lancet* 2013;382: 1575-86.
2. Murray CJ, Atkinson C, Bhalla K, et al. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. *JAMA* 2013; 310:591-608.
3. Ferrari AJ, Norman RE, Freedman G, et al. The burden attributable to mental and substance use disorders as risk factors for suicide: findings from the Global Burden of Disease Study 2010. *PLoS ONE* 2014;9:e91936.
4. WHO. The global burden of disease: 2004 update. Geneva, Switzerland: WHO Press, World Health Organization; 2008. Available: [www.who.int/healthinfo/global\\_burden\\_disease/GBD\\_report\\_2004update\\_full.pdf](http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf) (accessed 2015 June 3).
5. Rai D, Zitko P, Jones K, et al. Country- and individual-level socioeconomic determinants of depression: multilevel cross-national comparison. *Br J Psychiatry* 2013;202:195-203.
6. Cyranowski JM, Frank E, Young E, et al. Adolescent onset of the gender difference in lifetime rates of major depression: a theoretical model. *Arch Gen Psychiatry* 2000;57:21-7.
7. Ford DE, Erlinger TP. Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey. *Arch Intern Med* 2004;164:1010-4.
8. Baxter AJ, Scott KM, Ferrari AJ, et al. Challenging the myth of an "epidemic" of common mental disorders: trends in the global prevalence of anxiety and depression between 1990 and 2010. *Depress Anxiety* 2014;31:506-16.
9. Patten SB, Wang JL, Williams JV, et al. Descriptive epidemiology of major depression in Canada. *Can J Psychiatry* 2006;51:84-90.
10. Pearson C, Janz T, Ali J. Mental and substance use disorders in Canada. *Health at a Glance* 2013;1(September). Available: [www.statcan.gc.ca/pub/82-624-x/2013001/article/11855-eng.htm](http://www.statcan.gc.ca/pub/82-624-x/2013001/article/11855-eng.htm) (accessed 2015 June 3).
11. Bebbington P, Dunn G, Jenkins R, et al. The influence of age and sex on the prevalence of depressive conditions: report from the National Survey of Psychiatric Morbidity. *Int Rev Psychiatry* 2003; 15:74-83.
12. Rotermann M, Sanmartin C, Hennessy D, et al. Prescription medication use by Canadians aged 6 to 79. *Health Reports* 2014;25:1-9

Available: [www.statcan.gc.ca/pub/82-003-x/2014006/article/14032-eng.pdf](http://www.statcan.gc.ca/pub/82-003-x/2014006/article/14032-eng.pdf) (accessed 2015 June 3).

13. Kutcher S, Bagnell A, Wei Y. Mental health literacy in secondary schools: a Canadian approach. *Child Adolesc Psychiatr Clin N Am* 2015;24:233-44.
14. Bartels M, Cacioppo JT, van Beijsterveldt TC, et al. Exploring the association between well-being and psychopathology in adolescents. *Behav Genet* 2013;43:177-90.
15. Kendler KS, Gardner CO. Sex differences in the pathways to major depression: a study of opposite-sex twin pairs. *Am J Psychiatry* 2014;171:426-35.
16. Shively CA, Register TC, Friedman DP, et al. Social stress-associated depression in adult female cynomolgus monkeys (*Macaca fascicularis*). *Biol Psychol* 2005;69:67-84.
17. Willard SL, Friedman DP, Henkel CK, et al. Anterior hippocampal volume is reduced in behaviorally depressed female cynomolgus macaques. *Psychoneuroendocrinology* 2009;34:1469-75.
18. Shively CA, Friedman DP, Gage HD, et al. Behavioral depression and positron emission tomography-determined serotonin 1A receptor binding potential in cynomolgus monkeys. *Arch Gen Psychiatry* 2006;63:396-403.
19. Cohen LS, Soares CN, Vitonis AF, et al. Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles. *Arch Gen Psychiatry* 2006;63:385-90.
20. Gordon JL, Girdler SS. Hormone replacement therapy in the treatment of perimenopausal depression. *Curr Psychiatry Rep* 2014;16:517.
21. Lima FB, Centeno ML, Costa ME, et al. Stress sensitive female macaques have decreased fifth Ewing variant (Fev) and serotonin-related gene expression that is not reversed by citalopram. *Neuroscience* 2009;164:676-91.
22. Cheslack-Postava K, Keyes KM, Lowe SR, et al. Oral contraceptive use and psychiatric disorders in a nationally representative sample of women. *Arch Womens Ment Health* 2015;18:103-11.
23. Gillies GE, McArthur S. Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines. *Pharmacol Rev* 2010;62:155-98.
24. McEwen BS, Milner TA. Hippocampal formation: shedding light on the influence of sex and stress on the brain. *Brain Res Rev* 2007;55:343-55.
25. Warner M, Gustafsson JA. Estrogen receptor beta and liver X receptor beta: biology and therapeutic potential in CNS diseases. *Mol Psychiatry* 2015;20:18-22.

## JPN's top viewed articles\*

1. **N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action**  
Dean et al.  
*J Psychiatry Neurosci* 2011;36(2):78-86
2. **What is the best treatment for bipolar depression?**  
Young  
*J Psychiatry Neurosci* 2008;33(6):487-8
3. **On the neurobiology of hallucinations**  
Boksa  
*J Psychiatry Neurosci* 2009;34(4):260-2
4. **Biologic effects of mindfulness meditation: growing insights into neurobiologic aspects of the prevention of depression**  
Young  
*J Psychiatry Neurosci* 2011;36(2):75-7
5. **Maternal infection during pregnancy and schizophrenia**  
Boksa  
*J Psychiatry Neurosci* 2008;33(3):183-5
6. **Premenstrual dysphoric disorder: burden of illness and treatment update**  
Pearlstein and Steiner  
*J Psychiatry Neurosci* 2008;33(4):291-301

\*Based on page views on PubMed Central of content published in the last 7 years.  
Updated June 12, 2015.